Today, Marinus Pharmaceuticals Inc Inc (NASDAQ: MRNS) stock gained $ 0.21, an increase of 1.90%. Marinus opened at $ 11.04 before trading between $ 11.41 and $ 10.85 throughout Friday’s session. The activity saw Marinus’ market cap rise to $ 413,235,394 on 541,843 stocks, above their 30-day average of 222,093.
About Marinus Pharmaceuticals Inc
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapies to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-epileptic, anti-depressant and anti-anxiety potential. Ganaxolone is under development as intravenous and oral doses intended to maximize the therapeutic reach of adult and pediatric patient populations in acute and chronic care settings. Marinus recently completed the first-ever pivotal phase 3 trial in children with CDKL5 deficiency disorder and is conducting a phase 3 refractory status epilepticus trial, a phase 2 trial in tuberous sclerosis Bourneville and a phase 2 proof of concept trial on PCDH19. -related to epilepsy.
Visit the Marinus Pharmaceuticals Inc profile for more information.
About the Nasdaq Stock Market
The Nasdaq Stock Market is a global leader in trading data and services, as well as the listing of stocks and options. The Nasdaq is the world’s largest stock exchange for options volume and is home to the five largest US companies – Apple, Microsoft, Amazon, Alphabet and Facebook.
To get more information about Marinus Pharmaceuticals Inc and keep up with the latest company updates, you can visit the company profile page here: Marinus Pharmaceuticals Inc. Profile For more financial market information, no. be sure to visit Equities News. Also, don’t forget to sign up for the Daily Fix to get the best stories delivered to your inbox 5 days a week.
Sources: The chart is provided by TradingView on the basis of prices delayed by 15 minutes. All other data is provided by IEX Cloud as of 8:05 p.m. ET on the day of publication.
The views and opinions expressed in this article are those of the authors and do not represent the views of equities.com. Readers should not take the author’s statements as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please visit: http://www.equities.com/disclaimer
Federal Trade Commission steps up antitrust fight against Facebook
Deere beats third-quarter fiscal profit estimates; Increase annual forecasts
COVID-19 anxiety at highest level since winter: AP-NORC survey
$ 560 billion wiped off Chinese stock markets this week amid regulatory crackdowns
Biden administration to write off student loan debt of 300,000 severely disabled Americans
NATO official pledges to speed up evacuations out of Afghanistan
Republican governors fight with schools for mask mandates
Binance to demand tougher client background checks to fight money laundering